MedTrace Logo

Thromboelastography (TEG®) and Platelet Function in Patients on Anti-platelet Agents

NCT00901160 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2015-04-08

No results posted yet for this study

Summary

Can a post-operative analysis using a simple blood test (Thromboelastography(TEG®)) and Platelet Mapping Assay (PMA™) be able to detect the occurence of clotting or bleeding complications in patients on blood thinning (anti-platelet) agents?

Conditions

  • Blood Clotting

Interventions

PROCEDURE

blood test

Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.

Sponsors & Collaborators

  • University Health Network, Toronto

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • McMaster University

    lead OTHER

Principal Investigators

  • Summer Syed, M.D. · Hamilton Health Sciences Corporation

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-03-31
Completion
2011-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901160 on ClinicalTrials.gov